Genentech Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Genentech in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Report Highlights

[Studien Infos ausblenden]

CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 6
Genentech: PharmaVitae forecasts at a glance 8
Strategic insight 9
Genentech, the leading therapeutic monoclonal antibody player 9
Genentech to become a wholly owned subsidiary of Hoffman La Roche 10
Genentech's relationship with Roche was a key factor to success 10
Genentech's 'big three' 11
Successful 'land grab' locks out competition 12
Horizontal expansion of key products 13
Genentech's core growth 13
A multitude of future approvals for Avastin are the key driver 15
Complimentary approach: Genentech's integrated oncology portfolio 16
Genentech: Avastin-centered growth strategy 16
SWOT analysis 18
Strengths 18
Weaknesses 21
Opportunities 22
Threats 22
CHAPTER 3 QUARTERLY NEWS UPDATE 27
Quarterly sales update, Q408 27
Product developments 29
Deals and alliances 31
Product deals 31
Technology deals 33
M&A activity 35
Company announcements 36
Future product milestones 38
CHAPTER 4 COMPANY INTRODUCTION 39
Key findings 39
Background 40
Key corporate developments 41
Founding 41
Genentech's first product 41
Genentech's first mAb therapy 42
M&A history 44
Genentech's history with its partner Roche 44
Genentech's agreement with Roche 45
Roche's second offer for Genentech is accepted 47
CHAPTER 5 COMPANY SALES 48
Key findings 48
Prescription pharmaceutical sales and growth rate analysis, 2001-13 49
Product analysis 51
Product analysis, 2001-07 51
Product analysis, 2007-13 55
Therapy area analysis 59
Therapy area analysis, 2001-07 60
Therapy area analysis, 2001-07 60
Therapy area analysis, 2007-13 63
Therapy area focus, 2001-13 66
Geographic analysis 68
Geographic analysis, 2001-07 69
Geographic analysis, 2001-07 69
Geographic analysis, 2007-13 71
Geographic focus, 2001-13 73
Launch/core/expiry analysis 74
Explanation of launch/core/expiry analysis 74
Launch analysis, 2007-13 75
Core analysis, 2007-13 76
Expiry analysis, 2007-13 78
Launch/core/expiry configuration, 2007-13 79
Molecule type analysis 81
Molecule type analysis, 2001-07 82
Molecule type analysis, 2007-13 84
Externalization analysis 87
Externalization analysis, 2001-07 88
Externalization analysis, 2007-13 91
CHAPTER 6 COMPANY FINANCIALS 93
Key findings 93
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 94
Financial statements, 2001-07 97
Profit and loss account, 2001-07 97
Balance sheet, 2001-07 100
Operating costs and profit analysis 102
Operating costs and profit analysis, 2001-07 104
Operating cost ratio and profit margin analysis, 2001-07 105
Operating cost ratio and profit margin analysis, 2007-13 107
Operating costs and profit analysis, 2007-13 110
Return on capital employed analysis 112
Capital employed analysis, 2001-07 113
Capital employed analysis, 2001-07 113
Return on capital employed (RoCE) analysis, 2001-07 115
Market capitalization analysis 118
Market capitalization analysis, 2001-07 118
Total shareholder returns analysis, 2001-07 120
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 122
Key findings 122
Overview 123
Oncology 124
Avastin 124
Overview 124
Sales forecast 125
Rituxan 127
Overview 127
Sales forecast 128
Herceptin 130
Overview 130
Sales forecast 131
Tarceva 133
Overview 133
Sales forecast 134
Immunology & inflammation 136
Rituxan RA 136
Overview 136
Sales forecast 137
Ocrelizumab 139
Overview 139
Sales forecast 140
Other 142
Lucentis 142
Overview 142
Sales forecast 143
CHAPTER 8 APPENDIX 145
R&D pipeline 145
References 148
Datamonitor Reports 148
Abbreviations 148
[Inhaltsverzeichnis ausblenden]

Table 1: Genentech - PharmaVitae forecasts at a glance 8
Table 2: Genentech quarterly global sales update ($m), Q4 2008 27
Table 3: Genentech key product developments, 2008 29
Table 4: Genentech product deals and alliances, 2008 31
Table 5: Genentech technology deals and alliances, 2008 33
Table 6: Genentech M&A activity, 2008 35
Table 7: Genentech company announcements, 2008 36
Table 8: Genentech future product milestones, 2009-11 38
Table 9: Genentech product portfolio overview ($m), 2001-07 51
Table 10: Genentech product portfolio overview ($m), 2007-13 55
Table 11: Genentech portfolio by therapy area ($m), 2001-07 60
Table 12: Genentech portfolio by therapy area ($m), 2007-13 63
Table 13: Genentech portfolio overview by geographic region ($m), 2001-07 69
Table 14: Genentech portfolio overview by geographic region ($m), 2007-13 71
Table 15: Genentech launch portfolio overview ($m), 2007-13 75
Table 16: Genentech core portfolio overview ($m), 2007-13 76
Table 17: Genentech expiry portfolio overview ($m), 2007-13 78
Table 18: Genentech portfolio overview by molecule type ($m), 2001-07 82
Table 19: Genentech product portfolio overview by molecule type ($m), 2007-13 84
Table 20: Genentech product portfolio overview by source ($m), 2001-07 88
Table 21: Genentech product portfolio overview by source ($m), 2007-13 91
Table 22: Total Genentech sales by business unit ($m), 2001-07 94
Table 23: Genentech profit and loss account ($m), 2001-07 97
Table 24: Genentech balance sheet ($m), 2001-07 100
Table 25: Genentech operating revenue/cost analysis ($m), 2001-07 104
Table 26: Genentech operating cost ratio analysis (% of total revenues), 2001-07 105
Table 27: Genentech operating cost ratio analysis (% of total revenues), 2007-13 107
Table 28: Genentech operating revenue/cost analysis ($m), 2007-13 110
Table 29: Genentech capital employed ($m), 2001-07 113
Table 30: Genentech EBIT return on capital employed ($m), 2001-07 115
Table 31: Genentech EBIT pre-tax return/Capital employed driver analysis (%), 2001-07 116
Table 32: Genentech market capitalization ($ billion), 2001-07 118
Table 33: Genentech total shareholder returns (annual %), 2001-07 120
Table 34: Key products overview 123
Table 35: Avastin: overview 124
Table 36: Avastin: sales forecast ($m), 2007-13 125
Table 37: Rituxan: overview 127
Table 38: Rituxan: sales forecast ($m), 2007-13 128
Table 39: Herceptin: overview 130
Table 40: Herceptin: sales forecast ($m), 2007-13 131
Table 41: Tarceva: overview 133
Table 42: Tarceva: sales forecast ($m), 2007-13 134
Table 45: Rituxan RA: overview 136
Table 46: Rituxan RA: sales forecast ($m), 2007-13 137
Table 43: ocrelizumab: overview 139
Table 44: ocrelizumab: sales forecast ($m), 2007-13 140
Table 47: Lucentis: overview 142
Table 48: Lucentis: sales forecast ($m), 2007-13 143
Table 49: Genentech's R&D pipeline (Phase I-registration) 145
Table 50: Genentech's indication broadening pipeline (Phase I-registration) 146
Figure 1: Genentech prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: Genentech's financial performance ($m), 2001-13 7
Figure 3: Genentech launch/core/expiry configuration ($m), 2007-13 14
Figure 4: Avastin's potential approvals within the forecast period 15
Figure 5: Genentech's reliance on Avastin 17
Figure 6: Genentech SWOT analysis 18
Figure 7: Top 10 product sales ($m), forecast vs. actual, 2008 28
Figure 8: Genentech prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 49
Figure 9: Genentech key sales growth driver and resistors ($m), 2001-07 52
Figure 10: Genentech key sales growth drivers & resistors ($m), 2007-13 56
Figure 11: Genentech prescription pharmaceutical sales by therapy area ($m), 2001-13 59
Figure 12: Genentech prescription pharma sales by therapy area (% of total), 2001-13 66
Figure 13: Genentech prescription pharmaceutical sales by geographic region ($m), 2001-13 68
Figure 14: Genentech growth drivers and resistors by geographic region ($m), 2001-07 70
Figure 15: Genentech drivers and resistors by geographic region ($m), 2007-13 72
Figure 16: Genentech prescription pharmaceutical sales by geographic region (% of total), 2001-13 73
Figure 17: Genentech launch/core/expiry configuration ($m), 2007-13 79
Figure 18: Genentech prescription pharmaceutical sales by molecule type ($m), 2001-13 81
Figure 19: Genentech growth drivers and resistors by molecule type ($m), 2007-13 85
Figure 20: Genentech prescription pharmaceutical sales by source ($m), 2001-13 87
Figure 21: Genentech growth drivers and resistors by source ($m), 2001-07 89
Figure 22: Genentech growth drivers and resistors by source ($m), 2007-13 92
Figure 23: Genentech operating revenue/cost analysis ($m), 2001-13 103
Figure 24: Genentech operating cost ratio analysis (% of total revenues), 2001-13 108
Figure 25: Genentech return on capital employed, EBIT margin and capital turnover, 2001-07 112
Figure 26: Return on capital employed formula 116
Figure 27: Genentech market capitalization ($ billion), 2001-07 119
Figure 28: Genentech total shareholder returns vs. S&P 500 ($m), 2001-07 121
[Tabellenverzeichnis ausblenden]